News Release

IFCT-0302 results question role of CT-scan in NSCLC post-surgery follow-up

Study to be presented at ESMO 2017 Congress

Peer-Reviewed Publication

European Society for Medical Oncology

LUGANO-MADRID, Aug. 31, 2017 - The optimal follow-up protocol for patients with completely resected non-small cell lung cancer (NSCLC) remains elusive after results of the IFCT-0302 trial, presented at the ESMO 2017 Congress in Madrid (1), did not show a difference in overall survival (OS) between patients who received computed tomography (CT) scans as part of their follow-up, and those who did not.

Indeed, the findings suggest regular CT scans, which many guidelines recommend, may not be necessary.

"Because there is no difference between arms, both follow-up protocols are acceptable," said study investigator Prof. Virginie Westeel, from Centre Hospitalier Régional Universitaire, Hôpital Jean Minjoz in Besançon, France. "A conservative point of view would be to do a yearly CT-scan, which might be of interest over the long-term, however, doing regular scans every six months may be of no value in the first two post-operative years," she said.

The suggestion is a departure from standard clinical practice, since the majority of medical societies and clinical practice guidelines (2) recommend follow-up visits in which chest CT is considered appropriate every three to six months in the first two years after surgery.

The multicenter study included 1775 patients with completely resected stage I-II-IIIA NSCLC who completed follow-up visits every 6 months for the first two years, and yearly until five years.

Patients were randomised to a control follow-up, that included clinical examination and chest X-ray (CXR), or an experimental follow-up that included the control protocol with the addition of thoraco-abdominal CT-scan plus bronchoscopy (optional for adenocarcinomas). After a median follow-up of eight years and 10 months, overall survival (OS) was not significantly different between the groups (hazard ratio [HR] 0.95, 95% CI: 0.82-1.09; p=0.37) at a median of 99.7 months in the control arm and 123.6 months in the experimental arm.

Three-year disease-free survival rates were also similar, at 63.3% and 60.2% respectively, as were eight-year OS rates at 51.7% and 54.6%, respectively.

Commenting on the study, ESMO spokesperson Dr. Floriana Morgillo, from the University of Campania Luigi Vanvitelli, Naples, Italy, said that although the study does not demonstrate a significant benefit with CT-based follow-up, the trend towards better survival in the CT arm suggests longer follow-up may eventually reveal a benefit of this approach.

However, in the meantime, she says CT-based surveillance is still an appropriate option because of its potential for impacting second primary cancers. "A significant proportion of patients with early stage NSCLC develop second cancers between the second and fourth year after surgery, and early detection of these with CT-based surveillance beyond two years could allow curative treatment," Morgillo said, adding that patients must also be informed of the radiation exposure with CT.


Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO 2017 Congress


1 Abstract 1273O 'Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)' will be presented by Virginie Westeel during Presidential Symposium I on Saturday, 9 September 2017, 16:30 to 18:00 (CEST) in the Madrid Auditorium.

2 ESMO guidelines for Early-Stage and Locally Advanced (Non Metastatic) Non-Small Cell Lung Cancer


This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 16,000 members representing oncology professionals from over 130 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.